Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Vivian Fonseca
George Washington University, Department: Biostatistics & Other Math Sci
Should you be removed from our database? Contact us at [email protected]. Read more below.
Sanofi
Reimbursed or sponsored travel
Per the FCOI report filed on March 3. 2013, Dr. Fonseca disclosed that he has consulting relationships with two pharmaceutical companies ((b)(4) and Sanofi) that were selected by NIH to provide drugs to be used in the treatment regimens of the NIH sponsored study "Glycemia Reduction Approaches in Diabetes" GRADE. The Tulane Conflict of Interest Committee reviewed the disclosure and a description of the GRADE study established by NIH which sets forth that NIH selected drugs for the treatment regimen, blood analysis will be conducted by an NIH selected laboratory and additional monitoring of a patient participant will be done by the patient's primary care physician. The Conflict of Interest Committee determined that the conflict could be managed, because Dr. Fonseca has no influence in selection of drugs for the treatment regimen, the selection of the drugs/study arm for any participant will be made by a random computer selection, the lab results of the blood drawn will be analyzed by a laboratory selected by NIH and reports of lab results will be provided to NIH. In addition, Dr. Fonseca did not participate on any NIH Committees that selected the drugs to be used in the study. Dr. Fonseca advised the Tulane Conflict of Interest Committee that he is not on the GRADE executive committee nor does he serve as the lead principle investigator of the study. Dr. Fonseca is now adding travel to the consulting fees disclosure. There is no change to the value of the financial interest or the management plan.
Glycemia Reduction Approaches in Diabetes: A comparative effectiveness study
T2DM, a chronic disease with long-term complications, affects 25 million persons in the US. Clinical trials have established the importance of lowering glucose levels to delay or prevent complications of diabetes that cause more vision loss, kidney failure and amputations than any other disease. Still, the medications most likely to maintain goal glucose levels over time are unknown thus the GRADE study will identify the most effective means of treating T2DM, comparing drug effects on glucose levels, adverse effects, diabetes complications, and quality of life, and will have major public health implications.
Filed on July 20, 2013.
Tell us what you know about Vivian Fonseca's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Vivian Fonseca”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Vivian Fonseca | George Washington University | Conflict of Interest | Sanofi | $10,000 - $19,999 |
| Vivian Fonseca | George Washington University | Conflict of Interest | Sanofi | $10,000 - $19,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.